Vectofusin-1

Vectofusin-1 (12 μg/mL; 6 h) potently enhances the transduction efficiency of multiple lentiviral and retroviral pseudotypes in umbilical cord blood-derived hCD34⁺ hematopoietic stem/progenitor cells, resulting in a GFP⁺ cell proportion ranging from 57.5% to 79.4%, with no detectable cytotoxicity^[1].
Vectofusin-1 (0-35 μg/mL; 5 days) enhances the transduction efficiency of GALVTR-LV in umbilical cord blood-derived hCD34⁺ hematopoietic stem/progenitor cells, with an EC₅₀ of 6 μg/mL and a maximum average transduction efficiency of up to 67%^[1].
Vectofusin-1 (0-100 μg/mL; overnight) has a median toxic concentration (TC₅₀) of 60 μg/mL against umbilical cord blood-derived hCD34⁺ hematopoietic stem/progenitor cells, resulting in a 1-log safety index (TC₅₀/EC₅₀ = 10)^[1].
Vectofusin-1 (12 μg/mL) effectively enhances the transduction efficiency of VSV-G-pseudotyped lentiviral vectors in umbilical cord blood-derived hCD34⁺ hematopoietic stem and progenitor cells (HSPCs), with the proportion of GFP-positive cells ranging from 76.2% to 82.7% in both total cell and subset analyses, which is comparable to the efficacy of Retronectin^[2].
Vectofusin-1 (12 μg/mL) effectively enhances the transduction efficiency of VSV-G-pseudotyped lentiviral vectors in bone marrow-derived hCD34⁺ hematopoietic stem and progenitor cells (HSPCs); in analyses of total cells and subpopulations, the proportion of GFP-positive cells ranges from 69.8% to 74.8%, with a mean vector copy number (VCN) of 6.0 per cell, which is comparable to the efficacy of Retronectin^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.